News

Enlarge image

PolicyEUUK

Drug developers deeply concerned

28.11.2013 - EU industry associations urge EU legislators: Don’t make the regulatory process too long, putting Europe’s competitiveness at risk.

Just before Christmas, the European Commission, European Parliament and the EU Council are expected to finalise the Clinical Trials Regulation. However, drug developers and manufacturers are deeply concerned. They believe that the  compromise could fail to meet the original goal of the Regulation which was to reverse decreasing numbers of clinical trials carried out in the bloc.

In a joint statement EuropaBio, the European Federation of Pharma Industry Associations (EFPIA), the Association of Clinical Research Organisations (ACRO), Cancer Research UK, and the Patients Network for Medical Research and Health (EGAN) have urged the legislators not to dilute the original aim of the regulation:  "It is imperative to build on Europe’s innovative edge – not just for competitive reasons, but because innovation is the tool needed to deliver new and improved medicines to patients,“ they stress.  "The longer the regulatory process takes to approve a clinical trial, or process regulatory procedures around it, the greater the cost of the trial. Higher costs can result in fewer trials being run, reducing our ability to understand treatments better. Towards this end, we strongly support the path set out by the Commission as well as the European Parliament in ensuring competitive timelines for these authorisations, and urges the Council to support this approach moving forward.“

The associations say it is essential to ensure that timelines are predictable and are in no case longer than the timelines already established in the current Directive. The proposal of the Commission initially intended to shorten the Clinical Trial Authorisation Timeline from 60 days (90 days for advanced therapy medicinal products such as gene and cell therapies) to 25 days (plus 5 extra days for ATMPs). However as there are member states where the timeline is significantly longer, industry fears that the Council will prolong the timeline. According to EuropaBio "everything going beyond 60 days would clearly be uncompetitive and send the wrong signal“. 

Short timelines at high quality level, however, are possible. In the UK, the initial assessment is performed within 30 days, according to the MHRA. Applications for Healthy Volunteer Trials and sponsor-determined Phase I trials in non-oncology patients will be assessed and processed within 30 days, with an average of 14 days or less.

eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-04/eu-biopharma-industry-concerned.html

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

European UnionUKEU

24.06.2016 After the British people voted in favour of leaving the European Union, the industry is grappling with the profound impact this will likely have. Representatives from biotech industry, research and policits have expressed their concerns and hopes on the upcoming Brexit.

Investment FundUKIrelandEULuxembourg

24.06.2016 UK investment vehicle Malin has secured another €70m to invest in innovation and research across the European life sciences. The European Investment Bank will provide a debt facility over a period of seven years.

ImmunotherapyFranceEU

22.06.2016 TxCell has jumped on its option for a licensing agreement with the Weizmann Institute of Science’s tech transfer arm after it was granted a far-reaching patent for redirected, genetically engineered T regulatory cells by the EPO.

Clinical TrialsUK

21.06.2016 Circassia suffered a severe blow when its cat allergy immunotherapy failed to outcompete the placebo in a Phase III trial. The company’s shares, listed in London, plunged to a third of its previous value.

R&DSwitzerlandUK

16.06.2016 With support from the Medicines for Malaria Venture and Gates Foundation, Novartis will tackle resistant malaria with a new compound.

FinancingEUNetherlands

14.06.2016 European specialist investment firm Gilde Healthcare has closed its €250m fund for later stage and growth capital in medtech, digital health and therapeutics. The oversubscribed fund will invest in both Europe and North America.

AwardEUPortugalGermanyDenmarkFrance

09.06.2016 Exceptional inventors from all over Europe have been honoured with the European Inventor Award 2016. With the award, the European Patent Office recognises the achievements of inventors from Denmark, France, Germany, the Netherlands, the UK and the US.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • PLETHORA (UK)3.38 GBP12.67%
  • SCANCELL HOLDINGS (UK)16.25 GBP10.17%
  • ALMIRALL (E)12.42 EUR9.33%

FLOP

  • THERAMETRICS (CH)0.03 CHF-25.00%
  • EVOCUTIS (UK)0.04 GBP-20.00%
  • BIONOR PHARMA (N)0.56 NOK-11.11%

TOP

  • MDX HEALTH (B)3.79 EUR15.5%
  • ADDEX (CH)2.65 CHF15.2%
  • MEDIVIR (S)56.50 SEK13.7%

FLOP

  • SARTORIUS (D)68.49 EUR-72.4%
  • CIRCASSIA LIMITED (L)96.60 GBP-63.8%
  • VALNEVA (F)2.10 EUR-36.0%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)26.50 SEK1753.1%
  • NICOX (F)12.24 EUR558.1%

FLOP

  • BB BIOTECH (D)40.82 EUR-85.0%
  • EVOCUTIS (UK)0.04 GBP-81.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.40 SEK-78.8%

No liability assumed, Date: 30.06.2016